Onco3R Therapeutics has completed the first multiple-ascending-dose cohort in a Phase 1 study of its oral SIK3 inhibitor, O3R-5671,...

Biogen and Stoke Therapeutics unveiled new clinical and biomarker data for zorevunersen, an investigational antisense oligonucleotide for Dravet syndrome,...

XOMA Royalty Corporation has completed its acquisition of Mural Oncology plc via an Irish High Court–sanctioned scheme of arrangement,...

Rezolute reported topline data from its Phase 3 sunRIZE study in congenital hyperinsulinism showing that ersodetug did not meet...

Novartis will flood the 2025 ASH and SABCS meetings with more than 70 data readouts, including 11 oral presentations...

Mesoblast expects more than $30 million in gross revenue from Ryoncil (remestemcel‑l‑rknd) sales for the quarter ending December 31,...

Pacira BioSciences has filed patent infringement suits in the U.S. District Court for Delaware against The WhiteOak Group and...

HUTCHMED will deliver a coordinated slate of oncology and hematology readouts across ESMO Asia and ASH in early December,...

Dipharm a Francis has published an open-access method in Organic Process Research & Development that integrates the nitrosation assay...

Valneva reported final 12-month antibody persistence and safety results from its Phase 2 pediatric study of IXCHIQ, its single-shot...